Molecular radiotherapy (MRT) involves targeted delivery of ionising radiation to trigger localised cell death. Targeted irradiation is achieved using alpha (α) or beta (β-) emitting radionuclides that are incorporated into a radiopharmaceutical.
AIBN researcher Dr Nick Fletcher has won an Advance Queensland Industry Research Fellowship to explore localised cell death and the immune response to cancer.
Despite the remarkable ability of nanomedicines to diagnose and treat disease, activation of the immune system and the development of innate and adaptive immunity against specific subsets of nanomedicines is a significant unresolved challenge.
Targeted alpha-therapies (TATs) are emerging as powerful radiopharmaceutical tools for cancer treatment, allowing precise and localised dosing of highly potent radiotherapy.
Nanomedicine, the application of nanotechnology and biotechnology to medicine, is a rapidly expanding field of research with great promise for making meaningful changes in the way we treat many diseases including cancer.
In radiotherapeutics, a wide range of organic ligands have been designed to coordinate inorganic radioisotopes for diagnostic or therapeutic purposes. These ligands are typically conjugated to a targeting moiety through a linker; an organic bridge between the ligand and the targeting moiety.
